Ligand Pharmaceuticals
Price & Volume
Stats
See more52W Range | $67.72-$129.90 |
Market Cap | $2B |
Shares Short | 1M |
Financials
See moreRevenue (12 Mos) | $167.1M |
Revenue Growth (YoY) | 52.4% |
Gross Profit (12 Mos) | $134.6M |
Diluted EPS | -$0.22 |
News
See moreYahoo Finance • 15 days ago
Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
Yahoo Finance • 8 months ago
Roth analysis: Has volatility created a trigger warning for stocks?
Yahoo Finance • 10 months ago
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults
Yahoo Finance • 11 months ago
Ligand Pharmaceuticals First Quarter 2024 Earnings: EPS: US$4.86 (vs US$2.56 in 1Q 2023)
About
CEO | Mr. Todd C. Davis Ph.D. |
Address | 555 Heritage Drive, Jupiter, FL, United States, 33458 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 68 |
